← Eichor
Condition: Anaplastic Lymphoma Kinase Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Anaplastic Lymphoma Kinase

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT04322890Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Phase 3 · 1 location(s) · Queen Mary Hospital, Hong Kong · NCT06643416A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Ac
Phase 1/Phase 2 · 74 location(s) · Nuvalent Inc. · NCT05384626Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Pres
Phase 2 · 27 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT06620835Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05266846Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06234579Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie
Phase 1 · 45 location(s) · BioNTech SE · NCT05142189A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Phase 4 · 8 location(s) · University Medical Center Groningen · NCT05525338Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NA · 46 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT05122806Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Phase N/A · 1 location(s) · Sichuan Cancer Hospital and Research Institute · NCT06361589DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Canc
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770037Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Phase N/A · 1 location(s) · University of Colorado, Denver · NCT03042221Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Phase 3 · 157 location(s) · Nuvalent Inc. · NCT06765109Alectinib Pharmacokinetic in Patients With NSCLC
Phase 1/Phase 2 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT05713006DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05722886A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (AL
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07001384Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)
NA · 1 location(s) · Karolinska University Hospital · NCT05724004A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT05498064Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
EARLY_Phase 1 · 18 location(s) · Nationwide Children's Hospital · NCT06333899Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Phase 3 · 1 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT05341583A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small
Phase 2 · 9 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06378892
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.